Cassava Sciences updates on Phase 3 Alzheimer’s trial ahead of key readout

by
Contributor since / Followers

2 months ago

A federal registry on clinical trials indicated on Friday that Cassava Sciences (NASDAQ:SAVA) had completed its Phase 3 RETHINK-ALZ trial for its Alzheimer’s candidate simufilam, as the company is expected to generate its topline data before the year-end.
According to

Tags: SAVA